inflammatory diseases

News
AbbVie's Humira (adalimumab)

Novartis files Humira biosimilar in US

Novartis' Sandoz division has filed its biosimilar of Humira in the US, aiming to take a share of its multi-billion dollar revenues once its patent expires.

News
Boehringer Ingelheim Center (BIC)

Boehringer's Humira biosimilar approved in EU

AbbVie’s big-selling Humira will face competition from at least three biosimilars in Europe in around a year’s time, after the European Commission approved a biosimilar from Boehringer Inge